High rate of Ki-67 increase in entero-pancreatic NET relapses after surgery with curative intent.
Ki-67 change
disease recurrence
entero-pancreatic neuroendocrine tumors
heterogeneity
radical surgery
Journal
Journal of neuroendocrinology
ISSN: 1365-2826
Titre abrégé: J Neuroendocrinol
Pays: United States
ID NLM: 8913461
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
revised:
06
06
2022
received:
18
04
2022
accepted:
27
07
2022
entrez:
28
10
2022
pubmed:
29
10
2022
medline:
2
11
2022
Statut:
ppublish
Résumé
Neuroendocrine neoplasms (NENs) present with advanced disease at diagnosis in up to 28% of cases, precluding the possibility of curative-intent surgery. Histopathological heterogeneity of this disease can be observed inter-individually as well as intra-individually during disease course. The present study aimed to assess the frequency of Ki-67 change after radical surgery, in a series of patients with radically resected entero-pancreatic neuroendocrine tumors (EP-NETs). We present the analysis of a multicenter, retrospective, series of EP-NETs G1-G2 recurring after radical resection and with histological re-evaluation at disease recurrence (DR). The primary endpoint was the description of Ki-67 change at DR compared to time of surgery. The secondary endpoint was assessment of recurrence-free survival (RFS) rates. In total, 47 patients had a second histological evaluation and could be included in the present study. Median Ki-67 at surgery was 3% (range 1-15%) but, at DR, a significant increase in the value was observed (7%, range 1-30%; p < .01) and involved 66.0% of cases, with a corresponding increase in tumor grading in 34.0% (p = .05). Median RFS of the overall population was 40 months, and was worse when Ki-67 increased at DR vs. stable Ki-67 value (36 vs. 61 months, respectively; p = .02). In conclusion, in more than half of the cases with relapse after radical surgery, a higher proliferative index with a potentially more aggressive potential was observed. Therefore, histological reassessment should be considered on DR because tailored therapeutic strategies may be required for these patients.
Substances chimiques
Ki-67 Antigen
0
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13193Informations de copyright
© 2022 British Society for Neuroendocrinology.
Références
Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063-3072.
Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335-1342.
Rindi G, Kloppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006;449(4):395-401.
Rindi G, Kloppel G, Couvelard A, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2007;451(4):757-762.
WHO classification of Tumors Editorial Board. Digestive System Tumors. IARC Publications; 2019.
Grillo F, Albertelli M, Brisigotti MP, et al. Grade increases in Gastroenteropancreatic neuroendocrine tumor metastases compared to the primary tumor. Neuroendocrinology. 2016;103(5):452-459.
Singh S, Hallet J, Rowsell C, Law CH. Variability of Ki67 labeling index in multiple neuroendocrine tumors specimens over the course of the disease. Eur J Surg Oncol. 2014;40(11):1517-1522.
Keck KJ, Choi A, Maxwell JE, et al. Increased grade in neuroendocrine tumor metastases negatively impacts survival. Ann Surg Oncol. 2017;24(8):2206-2212.
Furukawa T, Ozaka M, Takamatsu M, et al. Ki-67 labeling index variability between surgically resected primary and metastatic hepatic lesions of Gastroenteropancreatic neuroendocrine neoplasms. Int J Surg Pathol. 2021;29(5):475-481.
Richards-Taylor S, Tilley C, Jaynes E, et al. Clinically significant differences in Ki-67 proliferation index between primary and metastases in resected pancreatic neuroendocrine tumors. Pancreas. 2017;46(10):1354-1358.
Shi H, Jiang C, Zhang Q, Qi C, Yao H, Lin R. Clinicopathological heterogeneity between primary and metastatic sites of gastroenteropancreatic neuroendocrine neoplasm. Diagn Pathol. 2020;15(1):108.
de Mestier L, Armani M, Cros J, et al. Lesion-by-lesion correlation between uptake at FDG PET and the Ki67 proliferation index in resected pancreatic neuroendocrine tumors. Dig Liver Dis. 2019;51(12):1720-1724.
Alexandraki KI, Kaltsatou M, Kyriakopoulos G, et al. Distinctive features of pancreatic neuroendocrine neoplasms exhibiting an increment in proliferative activity during the course of the disease. Endocrine. 2021;72(1):279-286.
Holmager P, Langer SW, Federspiel B, et al. Increase of Ki-67 index and influence on mortality in patients with neuroendocrine neoplasms. J Neuroendocrinol. 2021;33(9):e13018.
Panzuto F, Cicchese N, Partelli S, et al. Impact of Ki67 re-assessment at time of disease progression in patients with pancreatic neuroendocrine neoplasms. PLoS One. 2017;12(6):e0179445.
Knigge U, Capdevila J, Bartsch DK, et al. ENETS consensus recommendations for the standards of Care in Neuroendocrine Neoplasms: follow-up and documentation. Neuroendocrinology. 2017;105(3):310-319.
Bosman FT. WHO Classification of Tumours of the Digestive System. IARC Press; 2010.
Cros J, Theou-Anton N, Gounant V, et al. Specific genomic alterations in high-grade pulmonary neuroendocrine Tumours with carcinoid morphology. Neuroendocrinology. 2021;111(1-2):158-169.
Kloppel G, Couvelard A, Perren A, et al. ENETS consensus guidelines for the standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology. 2009;90(2):162-166.
Perren A, Couvelard A, Scoazec JY, et al. ENETS consensus guidelines for the standards of Care in Neuroendocrine Tumors: pathology: diagnosis and prognostic stratification. Neuroendocrinology. 2017;105(3):196-200.